Westmont

Researchers are evaluating the effect of semiconductor fabric sleeves on recovery after Anterior Cruciate Ligament ACL or ACL plus Meniscus arthroscopic surgery. The study aims to determine whether semiconductor sleeves improve functional outcomes and if they help patients recover faster compared to placebo sleeves that look similar but contain no semiconductor material. The trial is a randomized, double-blinded, placebo-controlled prospective clinical study led by the Illinois Center for Orthopaedic Research and Education. Participants will be assigned to one of three groups a control group receiving standard care, a group wearing semiconductor fabric sleeves, or a group wearing placebo sleeves without semiconductor material. The sleeves are worn post-operatively, with a leg sleeve worn for 4 weeks followed by a knee sleeve for 12 weeks, totaling 4 months of use. The intervention is delivered through these wearable devices, and the study compares their effects on recovery after surgery. During the study, participants will complete patient-reported outcome surveys and undergo clinical assessments including range of motion and effusion measurements up to one year after surgery. Researchers will monitor the functional progress and measure outcomes using validated tools to assess improvements. The total follow-up includes evaluations at one year to understand the longer-term effects of the sleeves on knee function after surgery.

Researchers are evaluating whether combining the investigational drug PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not yet received certain advanced anti-cancer treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have not been treated with androgen receptor signaling inhibitors like enzalutamide or abiraterone before, except for androgen deprivation therapy or first-generation anti-androgen agents. The study is sponsored by Pfizer and aims to assess treatment effects in this patient population. Participants will be randomly assigned to one of two groups one group will receive PF-06821497 875 mg twice daily combined with enzalutamide 160 mg once daily, while the other will receive a placebo twice daily plus enzalutamide 160 mg once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment continues over a period of up to approximately three years for primary outcomes, with ongoing assessments for up to five years for some secondary outcomes. During the study, participants will undergo various assessments including scans to monitor disease progression, blood tests to measure prostate-specific antigen levels and circulating tumor DNA, patient-reported pain and quality of life questionnaires, and evaluations of adverse events. The primary outcome is radiographic progression-free survival measured from randomization up to about three years. Safety and long-term effects will be monitored through follow-up visits lasting up to five years. Participants will be followed closely throughout the study duration to track treatment impact and side effects.